Skip to content

ixX pharma

Active
Public limited companyfounded 2005active for 21 yearsBorsbeeksebrug 34, 2600 Antwerpen, Belgium103 active companies are registered at this addressKBO/BCE: BE 0873.490.740
Summary

ixX pharma has been active since 2005 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €6.9m and a net result of €1.7m. Equity is growing by about 12% per year across the filed financial years. Its solvency ranks better than 68% of 6,136 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).

Risk analysisFollow ReportCompare
ixX pharmaActiveChecked score 92/100
Risk analysis ReportCompare

Overview

Activity
Wholesale of pharmaceutical and medical goods
NACE 46460
1 site
Size
€11.6mturnover 2025
Staff
26.3 FTE
Equity
€6.9m
Profit
€1.7m
Financial health
92 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.2%
Structure
Parent
PONROY VITARMONYL BENELUX · 100%
Holdings
1
Auditor: KPMG Bedrijfsrevisoren BV2025 accounts filed 31 days late8 of 16 deeds summarised
Why 92raises risk1 change of registered office in 24 monthslowers riskSize: turnover €11.6m, 26.3 FTE, total assets €11.3mFounded in 2005Profit of €1.7m (financial year 2025)Show the evidence

Checked score

Score 2025
92 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 66% of its sector peers (NACE 46, small)
Every signal that counts is listed under Signals.
Financial strength · tick = 2024
Strong
Solvency 86=
equity 61.4% of total assets
Liquidity 47-1
short-term debt 38.6% · cash 12.0%
Profitability 91+8
return on assets 15.0%
Bankruptcy probability, 12 months
0.2% Very low
0%0.5%1.5%4%10%≥ 25%

About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.2% (4,376 companies, NACE 46, small)
Last 24 months 11-2024: < 0.1% 12-2024: < 0.1%● unchanged vs 11-2024 01-2025: < 0.1%● unchanged vs 12-2024 02-2025: < 0.1%● unchanged vs 01-2025lowest value 03-2025: < 0.1%● unchanged vs 02-2025lowest value 04-2025: < 0.1%● unchanged vs 03-2025 05-2025: < 0.1%● unchanged vs 04-2025 06-2025: < 0.1%● unchanged vs 05-2025 07-2025: 0.1%▲ +0.1 percentage points vs 06-2025 08-2025: 0.2%▲ +0.1 percentage points vs 07-2025 09-2025: 0.1%▼ -0.1 percentage points vs 08-2025 10-2025: 0.1%● unchanged vs 09-2025 11-2025: 0.1%● unchanged vs 10-2025 12-2025: 0.1%● unchanged vs 11-2025 01-2026: 0.1%● unchanged vs 12-2025 02-2026: 0.1%● unchanged vs 01-2026 03-2026: 0.1%● unchanged vs 02-2026 04-2026: 0.1%● unchanged vs 03-2026 05-2026: 0.1%● unchanged vs 04-2026 06-2026: 0.1%● unchanged vs 05-2026 07-2026: 0.1%● unchanged vs 06-2026 08-2026: 0.2%▲ +0.1 percentage points vs 07-2026highest value 09-2026: 0.2%● unchanged vs 08-2026 10-2026: 0.2%● unchanged vs 09-2026
Credit of up to €600,000 on 30-day terms is acceptable
Liquidity ample (current ratio 2.18, compared with 2.38 in 2024, above the usual 1.5; short-term debt: 38.6% and cash: 12% of total assets), and 38.6% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, small): better than 71% on solvency, 56% on liquidity, 93% on profitability and 43% on growth.

The bankruptcy probability was computed on 23-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
lowers riskraises risk
raises risk · 1 change of registered office in 24 months
Belgian Official Gazette
lowers risk · Size: turnover €11.6m, 26.3 FTE, total assets €11.3m
Companies of this size fail less often; how much that weighs depends on the rest of its profile.
NBB · annual accounts
lowers risk · Founded in 2005
Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.
KBO
lowers risk · Profit of €1.7m (financial year 2025)
NBB · annual accounts
raises risk · 2025 accounts filed 31 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 31-08-2026, 31 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filings
Deviation from the deadline
2025
31 days late
2024
27 days late
2023
36 days early
2022
20 days early
2021
11 days early
2020
26 days early
2019
24 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 2 days before the deadline; the sector median (NACE 46) for financial year 2024 is 3 days before the deadline, and 39% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 20 July (4 of the last 5 filed years within 38 days of that day).
Companies Code · seven months
Where today falls in the filing period
24-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · full…
  2. Capital & shares · RestructuringMerger
  3. RestructuringMerger · Declaration · Proposal

Key points

  • Positive: Among the best 13% on net resultsector median €112,676 · 6,071 companies €1.7m View
  • Board changedlatest change 30-04-2026 · 0 in office 2 joined · 1 left View
  • Positive: 8 profitable years in a rowprofit 2025: €1.7m 8 years View
  • Controlled by PONROY VITARMONYL BENELUXultimately: Bon Topco 100% View
  • Merger with BIOCYTE BENELUXmerger on 01-01-2026 2026 View
  • Positive: Result rose in 2025from €1.2m to €1.7m ▲ 40.3% View

By topic

Financials

Financial year
2025
Turnover
€11.6m
Profit
€1.7m
Solvency
61.4%
Turnover▼ 8.9%
Net result
20212025
Go to Financials

Network & group

Group
Bon Topco
Subsidiaries
1
Mergers and asset contributions
1

1 subsidiary

Go to Network & group

Timeline

Events
32
Since
2007
Next accounts
by 31-07-2027
  1. 05-06-2026Resignation: Benjamin Francq (day-to-day manager)
  2. 27-08-2025Annual accounts filed
  3. 24-07-2025Registered office
Go to Timeline

Company details

Sites
1
Legal form
Public limited company
Activity
Wholesale of pharmaceutical and medical goodsNACE 46460
Founded
26-04-2005
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Articles of association

Provisions read
8
Purpose
“De ontwikkeling, productie, commercialisatie, opslag en distributie van farmaceutische…” (deed in Dutch)
Go to Articles of association

Key facts about ixX pharma

What is the company number of ixX pharma?
0873.490.740. In Belgium the VAT number is the company number with BE in front: BE 0873.490.740.
Where is ixX pharma based?
The registered office is at Borsbeeksebrug 34, 2600 Antwerpen.Company details
What does ixX pharma do?
According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
What is the legal form of ixX pharma?
Public limited company (NV).
When was ixX pharma founded?
On 26-04-2005.
Is ixX pharma still active?
Yes, ixX pharma is an active enterprise in the KBO register.
How many employees does ixX pharma have?
On average 26.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of ixX pharma?
€11.6m in financial year 2025, according to the filed annual accounts.
Is ixX pharma profitable?
In financial year 2025, ixX pharma made a profit of €1.7m.
Where can I find the annual accounts of ixX pharma?
ixX pharma filed 20 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of ixX pharma due?
By 31-07-2027, for financial year 2026.Timeline

Companies related to ixX pharma

Go further with this company

How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Is the workforce growing, and do people stay?Employer check Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure